ASR Vermogensbeheer N.V. Cuts Stock Holdings in Edwards Lifesciences Corporation $EW

ASR Vermogensbeheer N.V. reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 0.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 83,053 shares of the medical research company’s stock after selling 337 shares during the period. ASR Vermogensbeheer N.V.’s holdings in Edwards Lifesciences were worth $6,496,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Nuveen LLC purchased a new position in shares of Edwards Lifesciences during the first quarter valued at about $330,881,000. Jennison Associates LLC lifted its position in shares of Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after buying an additional 2,576,383 shares in the last quarter. Woodline Partners LP boosted its stake in Edwards Lifesciences by 7,805.0% during the first quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock valued at $59,822,000 after buying an additional 814,917 shares during the last quarter. AQR Capital Management LLC grew its holdings in Edwards Lifesciences by 339.7% during the 1st quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company’s stock valued at $65,381,000 after buying an additional 709,648 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Edwards Lifesciences by 37.0% in the 1st quarter. BNP Paribas Financial Markets now owns 1,946,818 shares of the medical research company’s stock worth $141,105,000 after acquiring an additional 525,822 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.5%

Shares of EW opened at $76.66 on Friday. The company’s fifty day simple moving average is $78.55 and its 200-day simple moving average is $75.89. The company has a market cap of $45.01 billion, a P/E ratio of 11.03, a P/E/G ratio of 3.67 and a beta of 1.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm’s revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research reports. Wells Fargo & Company increased their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research report on Thursday, August 7th. Stifel Nicolaus set a $85.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Monday, September 22nd. Argus upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Thursday, July 10th. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Finally, Barclays upped their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.61.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.